Edwards Lifesciences Corporatio

Valuation Analysis

About the Company

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distr

Edwards Lifesciences Corporatio Stock at a Glance

Edwards Lifesciences Corporatio (EW) is currently trading at $85.11 with a market capitalization of $49B. The trailing P/E ratio stands at 46.01x, with a forward P/E of 25.27x. The 52-week range spans from $72.30 to $89.48; the current price is 4.9% below the yearly high. Year-over-year revenue growth stands at +16.7%. The net profit margin stands at 17.39%.

💰 Dividend

Edwards Lifesciences Corporatio currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

26 analysts rate Edwards Lifesciences Corporatio (EW) on consensus: Buy. The average price target is $96.92, implying +13.88% from the current price. Analyst price targets range from $84.00 to $110.00.

Edwards Lifesciences Corporatio: The Investment Case in Detail

Edwards Lifesciences Corporatio (EW) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 16.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 77.87%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 17.39%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

What to Watch Next

• The forward P/E of 25.27x is meaningfully below the trailing 46.01x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Edwards Lifesciences Corporatio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.